Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China.

Abstract

Background: The cost-effectiveness of tislelizumab plus chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC) was uncleared yet. The current analysis aimed to evaluate the cost-effective of adding tislelizumab to the first-line chemotherapy for patients with untreated ES-SCLC from the Chinese health-care system perspective.

Research design and methods: A partitioned survival model that simulated 3-week patients transition in 10-year time horizon was established to evaluate the economic value. The clinical benefit and safety data were gathered from the RATIONALE-312 trial, model parameters were gathered from the local charges and previously published studies. Sensitivity analyses and subgroup analyses were conducted to examine the robustness of the model outcomes.

Results: Tislelizumab plus chemotherapy could bring additional 0.61 LYs and 0.30 QALYs with the marginal cost of $5,849.40, resulting in the incremental cost-effectiveness ratio (ICER) of $19,592.08 per additional quality-adjusted life-years (QALYs) gained. Sensitivity analyses and subgroup analyses confirmed the robustness of the model results for both intention-to-treat patients and all subgroup patients.

Conclusions: Tislelizumab plus chemotherapy could be considered cost-effective first-line therapy for patients with untreated ES-SCLC patients compared with chemotherapy alone from the perspective of Chinese health-care system.